FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:UBQLN1-TLE1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: UBQLN1-TLE1
FusionPDB ID: 96407
FusionGDB2.0 ID: 96407
HgeneTgene
Gene symbol

UBQLN1

TLE1

Gene ID

29979

7088

Gene nameubiquilin 1TLE family member 1, transcriptional corepressor
SynonymsDA41|DSK2|PLIC-1|UBQN|XDRP1ESG|ESG1|GRG1
Cytomap

9q21.32|9q21.2-q21.3

9q21.32

Type of geneprotein-codingprotein-coding
Descriptionubiquilin-1hPLIC-1protein linking IAP with cytoskeleton 1testicular tissue protein Li 219transducin-like enhancer protein 1enhancer of split groucho-like protein 1transducin like enhancer of split 1transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
Modification date2020032720200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000257468, ENST00000376395, 
ENST00000376472, ENST00000376463, 
ENST00000376484, ENST00000464999, 
ENST00000376499, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 12 X 8=13446 X 6 X 3=108
# samples 166
** MAII scorelog2(16/1344*10)=-3.0703893278914
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(6/108*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: UBQLN1 [Title/Abstract] AND TLE1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: UBQLN1 [Title/Abstract] AND TLE1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)UBQLN1(86322414)-TLE1(84235472), # samples:1
Anticipated loss of major functional domain due to fusion event.UBQLN1-TLE1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
UBQLN1-TLE1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
UBQLN1-TLE1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
UBQLN1-TLE1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneUBQLN1

GO:0031396

regulation of protein ubiquitination

12634373

HgeneUBQLN1

GO:0031398

positive regulation of protein ubiquitination

23307288

HgeneUBQLN1

GO:0035973

aggrephagy

21143716

TgeneTLE1

GO:0043124

negative regulation of I-kappaB kinase/NF-kappaB signaling

17680780

TgeneTLE1

GO:0045892

negative regulation of transcription, DNA-templated

9751710



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:86322414/chr9:84235472)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across UBQLN1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across TLE1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000376395UBQLN1chr986322414-ENST00000376499TLE1chr984235472-29387045242422632
ENST00000257468UBQLN1chr986322414-ENST00000376499TLE1chr984235472-26694352552153632

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000376395ENST00000376499UBQLN1chr986322414-TLE1chr984235472-0.0030636640.9969363
ENST00000257468ENST00000376499UBQLN1chr986322414-TLE1chr984235472-0.0031802960.99681973

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for UBQLN1-TLE1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
UBQLN1chr986322414TLE1chr98423547243557KEKEEFAVPENSSVQQSNSLLVPDSL
UBQLN1chr986322414TLE1chr98423547270457KEKEEFAVPENSSVQQSNSLLVPDSL

Top

Potential FusionNeoAntigen Information of UBQLN1-TLE1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
UBQLN1-TLE1_86322414_84235472.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:03FAVPENSSV0.98970.9097514
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:02FAVPENSSV0.98680.9701514
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:04FAVPENSSV0.98680.9701514
UBQLN1-TLE1chr986322414chr984235472435HLA-B51:01FAVPENSSV0.9750.5183514
UBQLN1-TLE1chr986322414chr984235472435HLA-A02:21FAVPENSSV0.91080.6106514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:17AVPENSSV0.97850.9552614
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:30AVPENSSV0.82310.9632614
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:07FAVPENSSV0.99980.9878514
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:06FAVPENSSV0.99960.9326514
UBQLN1-TLE1chr986322414chr984235472435HLA-C04:06FAVPENSSV0.99940.8824514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:19FAVPENSSV0.99930.9922514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:07SSVQQSNSL0.99920.95361120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:19SSVQQSNSL0.99910.96921120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:08SSVQQSNSL0.99910.86051120
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:06SSVQQSNSL0.99880.82311120
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:13FAVPENSSV0.99860.9759514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:04FAVPENSSV0.99860.9759514
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:04FAVPENSSV0.99780.9954514
UBQLN1-TLE1chr986322414chr984235472435HLA-C06:03FAVPENSSV0.99750.9955514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:08FAVPENSSV0.99640.9158514
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:12FAVPENSSV0.99570.9593514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:03FAVPENSSV0.99180.9868514
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:12FAVPENSSV0.98680.9701514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:13SSVQQSNSL0.97550.90191120
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:04SSVQQSNSL0.97550.90191120
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:17SSVQQSNSL0.9720.92111120
UBQLN1-TLE1chr986322414chr984235472435HLA-B51:07FAVPENSSV0.97020.9291514
UBQLN1-TLE1chr986322414chr984235472435HLA-B78:01FAVPENSSV0.96610.6028514
UBQLN1-TLE1chr986322414chr984235472435HLA-C05:09FAVPENSSV0.96060.9056514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:17FAVPENSSV0.94760.9576514
UBQLN1-TLE1chr986322414chr984235472435HLA-C06:03SSVQQSNSL0.94460.97831120
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:12SSVQQSNSL0.94190.85341120
UBQLN1-TLE1chr986322414chr984235472435HLA-C02:06FAVPENSSV0.91990.9852514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:30SSVQQSNSL0.8890.92481120
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:15FAVPENSSV0.83520.9505514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:03SSVQQSNSL0.79680.96451120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:14FAVPENSSV0.74330.9859514
UBQLN1-TLE1chr986322414chr984235472435HLA-C02:06SSVQQSNSL0.7110.95071120
UBQLN1-TLE1chr986322414chr984235472435HLA-B14:03SSVQQSNSL0.66690.67471120
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:03AVPENSSV0.98220.9364614
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:02AVPENSSV0.97520.9545614
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:05FAVPENSSV0.99960.8922514
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:02FAVPENSSV0.99960.897514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:17FAVPENSSV0.99950.9791514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:05FAVPENSSV0.99950.95514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:03SSVQQSNSL0.99920.98611120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:04SSVQQSNSL0.99920.98611120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:06FAVPENSSV0.99890.9938514
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:05SSVQQSNSL0.99850.81291120
UBQLN1-TLE1chr986322414chr984235472435HLA-C15:02SSVQQSNSL0.99840.76991120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:17SSVQQSNSL0.9980.96671120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:04FAVPENSSV0.9980.9932514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:03FAVPENSSV0.9980.9932514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:67FAVPENSSV0.9980.985514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:67SSVQQSNSL0.99780.97391120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:05SSVQQSNSL0.99770.90871120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:02FAVPENSSV0.99740.9827514
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:03FAVPENSSV0.9970.9879514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:02SSVQQSNSL0.99630.95851120
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:04FAVPENSSV0.99560.9906514
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:02FAVPENSSV0.99220.9828514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:01FAVPENSSV0.99180.9868514
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:09FAVPENSSV0.98680.9701514
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:13FAVPENSSV0.9830.9122514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:02SSVQQSNSL0.97490.92031120
UBQLN1-TLE1chr986322414chr984235472435HLA-B78:02FAVPENSSV0.97460.7363514
UBQLN1-TLE1chr986322414chr984235472435HLA-A68:02FAVPENSSV0.97020.5881514
UBQLN1-TLE1chr986322414chr984235472435HLA-B51:14FAVPENSSV0.96610.5114514
UBQLN1-TLE1chr986322414chr984235472435HLA-A69:01FAVPENSSV0.96590.7133514
UBQLN1-TLE1chr986322414chr984235472435HLA-C04:03FAVPENSSV0.96120.7938514
UBQLN1-TLE1chr986322414chr984235472435HLA-C05:01FAVPENSSV0.96060.9056514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:03SSVQQSNSL0.95940.85071120
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:03SSVQQSNSL0.95070.95191120
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:03FAVPENSSV0.94150.9283514
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:02FAVPENSSV0.93720.9558514
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:06SSVQQSNSL0.9290.98381120
UBQLN1-TLE1chr986322414chr984235472435HLA-B51:21FAVPENSSV0.92690.5189514
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:02FAVPENSSV0.9220.9908514
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:04SSVQQSNSL0.91530.94641120
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:03SVQQSNSLL0.91320.84541221
UBQLN1-TLE1chr986322414chr984235472435HLA-A02:14FAVPENSSV0.91110.5226514
UBQLN1-TLE1chr986322414chr984235472435HLA-A02:06FAVPENSSV0.91080.6106514
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:01FAVPENSSV0.89290.9818514
UBQLN1-TLE1chr986322414chr984235472435HLA-C12:02SSVQQSNSL0.88610.93281120
UBQLN1-TLE1chr986322414chr984235472435HLA-C01:02SVQQSNSLL0.86580.92411221
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:02FAVPENSSV0.83520.9505514
UBQLN1-TLE1chr986322414chr984235472435HLA-C07:04FAVPENSSV0.83210.8918514
UBQLN1-TLE1chr986322414chr984235472435HLA-C17:01FAVPENSSV0.82110.9709514
UBQLN1-TLE1chr986322414chr984235472435HLA-C02:02FAVPENSSV0.80210.989514
UBQLN1-TLE1chr986322414chr984235472435HLA-C02:10FAVPENSSV0.80210.989514
UBQLN1-TLE1chr986322414chr984235472435HLA-C08:01SSVQQSNSL0.79680.96451120
UBQLN1-TLE1chr986322414chr984235472435HLA-B07:13SVQQSNSLL0.79610.79451221
UBQLN1-TLE1chr986322414chr984235472435HLA-B35:13SSVQQSNSL0.75740.83771120
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:02SSVQQSNSL0.73940.98741120
UBQLN1-TLE1chr986322414chr984235472435HLA-C03:06SVQQSNSLL0.72980.98331221
UBQLN1-TLE1chr986322414chr984235472435HLA-C16:01SSVQQSNSL0.72520.96761120
UBQLN1-TLE1chr986322414chr984235472435HLA-C17:01SSVQQSNSL0.64530.87831120
UBQLN1-TLE1chr986322414chr984235472435HLA-B15:30SSVQQSNSL0.64470.65091120
UBQLN1-TLE1chr986322414chr984235472435HLA-B15:73SSVQQSNSL0.64360.73961120
UBQLN1-TLE1chr986322414chr984235472435HLA-B07:13FAVPENSSV0.62510.8607514
UBQLN1-TLE1chr986322414chr984235472435HLA-B07:13SSVQQSNSL0.39480.79191120
UBQLN1-TLE1chr986322414chr984235472435HLA-B15:73SVQQSNSLL0.3090.69511221
UBQLN1-TLE1chr986322414chr984235472435HLA-B15:30SVQQSNSLL0.26940.59981221
UBQLN1-TLE1chr986322414chr984235472435HLA-A68:02EFAVPENSSV0.73580.5421414

Top

Potential FusionNeoAntigen Information of UBQLN1-TLE1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
UBQLN1-TLE1_86322414_84235472.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
UBQLN1-TLE1chr986322414chr984235472435DRB1-0701NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0701ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0701PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0703NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0703ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0703PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0704NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0704ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0705NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0705ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0705PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0706NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0706ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0707NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0707ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0707PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0708NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0708ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0708PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0709NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0709ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0709PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0711NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0711ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0712NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0712ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0712PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0713NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0713ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0713PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0714NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0714ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0714PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0715NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0715ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0715PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0716NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0716ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0716PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0717NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0717ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0717PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0719NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0719ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0719PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0901NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0901ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0904NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0904ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0904PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0905NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0905ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0906NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0906ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0906PENSSVQQSNSLLVP823
UBQLN1-TLE1chr986322414chr984235472435DRB1-0906SSVQQSNSLLVPDSL1126
UBQLN1-TLE1chr986322414chr984235472435DRB1-0907NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0907ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-0909NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-0909ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-1404NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1410NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1410ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-1428NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1439NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1439ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-1450NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1450ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-1461NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1470NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1470ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB1-1471NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1482NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1525NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB1-1525ENSSVQQSNSLLVPD924
UBQLN1-TLE1chr986322414chr984235472435DRB3-0301NSSVQQSNSLLVPDS1025
UBQLN1-TLE1chr986322414chr984235472435DRB3-0301ENSSVQQSNSLLVPD924

Top

Fusion breakpoint peptide structures of UBQLN1-TLE1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
699AVPENSSVQQSNSLUBQLN1TLE1chr986322414chr984235472435

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of UBQLN1-TLE1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN699AVPENSSVQQSNSL-5.97758-6.09098
HLA-B14:023BVN699AVPENSSVQQSNSL-5.15013-6.18543
HLA-B52:013W39699AVPENSSVQQSNSL-6.29935-6.41275
HLA-B52:013W39699AVPENSSVQQSNSL-6.07479-7.11009
HLA-A24:025HGA699AVPENSSVQQSNSL-7.25246-8.28776
HLA-A24:025HGA699AVPENSSVQQSNSL-6.23064-6.34404
HLA-B44:053DX8699AVPENSSVQQSNSL-4.66421-5.69951
HLA-B44:053DX8699AVPENSSVQQSNSL-4.52141-4.63481
HLA-A02:016TDR699AVPENSSVQQSNSL-7.72945-7.84285

Top

Vaccine Design for the FusionNeoAntigens of UBQLN1-TLE1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
UBQLN1-TLE1chr986322414chr9842354721120SSVQQSNSLCAGCAGAGTAATTCCCTCCTGGTCCCA
UBQLN1-TLE1chr986322414chr9842354721221SVQQSNSLLCAGAGTAATTCCCTCCTGGTCCCAGAC
UBQLN1-TLE1chr986322414chr984235472414EFAVPENSSVGTGCCCGAGAATAGCTCCGTCCAGCAGAGT
UBQLN1-TLE1chr986322414chr984235472514FAVPENSSVCCCGAGAATAGCTCCGTCCAGCAGAGT
UBQLN1-TLE1chr986322414chr984235472614AVPENSSVGAGAATAGCTCCGTCCAGCAGAGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
UBQLN1-TLE1chr986322414chr9842354721025NSSVQQSNSLLVPDSGTCCAGCAGAGTAATTCCCTCCTGGTCCCAGACAGTCTAAGAGGC
UBQLN1-TLE1chr986322414chr9842354721126SSVQQSNSLLVPDSLCAGCAGAGTAATTCCCTCCTGGTCCCAGACAGTCTAAGAGGCACA
UBQLN1-TLE1chr986322414chr984235472823PENSSVQQSNSLLVPAGCTCCGTCCAGCAGAGTAATTCCCTCCTGGTCCCAGACAGTCTA
UBQLN1-TLE1chr986322414chr984235472924ENSSVQQSNSLLVPDTCCGTCCAGCAGAGTAATTCCCTCCTGGTCCCAGACAGTCTAAGA

Top

Information of the samples that have these potential fusion neoantigens of UBQLN1-TLE1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerUBQLN1-TLE1chr986322414ENST00000257468chr984235472ENST00000376499271N

Top

Potential target of CAR-T therapy development for UBQLN1-TLE1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to UBQLN1-TLE1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to UBQLN1-TLE1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource